From the 2nd Department of Surgery, Aretaieio University Hospital, Athens School of Medicine, National & Kapodistrian University of Athens, Athens, Greece.
Pancreas. 2021 Oct 1;50(9):1250-1253. doi: 10.1097/MPA.0000000000001921.
Pancreatic adenocarcinoma remains a chemotherapy-resistant and refractory malignancy with high mortality, unaffected by recent progress in anticancer treatment. Expression of estrogen receptors was detected almost 50 years ago, in both benign and malignant pancreatic cells. However, early preclinical studies in pancreatic cancer led to contradictory findings, and most clinical studies failed to demonstrate an effect with tamoxifen treatment. The identification of a second form of estrogen receptor seems to provide some explanation for these discrepancies. Predominantly expressed in malignant cells and structurally different from what was considered the only estrogen receptor, estrogen receptor β was recognized as a negative prognostic factor and a possible therapeutic target in pancreatic ductal adenocarcinoma. Therefore, findings of research before the identification of estrogen receptor β should be reconsidered, and further studies should be designed to reassess the expression and effect of this specific estrogen receptor type in pancreatic cancer.
胰腺导管腺癌仍然是一种化疗耐药和难治的恶性肿瘤，死亡率高，不受近年来抗癌治疗进展的影响。雌激素受体的表达在近 50 年前就被发现，存在于良性和恶性胰腺细胞中。然而，早期在胰腺癌中的临床前研究得出了相互矛盾的结果，大多数临床研究未能证明他莫昔芬治疗有效。第二种形式的雌激素受体的发现似乎为这些差异提供了一些解释。雌激素受体 β 主要在恶性细胞中表达，与被认为是唯一的雌激素受体在结构上不同，被认为是胰腺导管腺癌的一个不良预后因素和可能的治疗靶点。因此，在鉴定出雌激素受体 β 之前的研究结果应该重新考虑，并且应该设计进一步的研究来重新评估这种特定的雌激素受体类型在胰腺癌中的表达和作用。
